ESC 365 - The relationship between changes of antithrombotic drug regimen after ischemic stroke and risks of clinical outcomes in patients with atrial fibrillation

ESC Professional Premium Access

The relationship between changes of antithrombotic drug regimen after ischemic stroke and risks of clinical outcomes in patients with atrial fibrillation

Session: Atrial fibrillation and stroke: role of kidney disease and biomarkers

Topic: Stroke in Atrial Fibrillation

Speaker: Doctor T. Chao (Taipei, TW)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Doctor Tze-Fan Chao

Taipei Veterans General Hospital, Taipei (Taiwan)

4 presentations

0 follower

3 more presentations in this session

Stroke, mortality, and major bleeding among patients with atrial fibrillation and chronic kidney disease; insights from a contemporary large-scale population study

Speaker: Doctor Y. Ben Baruch Golan (Beer Sheva, IL)

Kidney function by creatinine and cystatin c and adverse cardiovascular outcomes in patients with atrial fibrillation

Speaker: Mr A. Schweigler (Basel, CH)

Neurofilament light chain (NFL) - a neuron-specific plasma biomarker for evaluating risk of ischemic cerebral events in atrial fibrillation

Speaker: Doctor J. Aulin (Uppsala, SE)

Access the full session

Atrial fibrillation and stroke: role of kidney disease and biomarkers

Speakers: Doctor T. Chao, Doctor Y. Ben Baruch Golan, Mr A. Schweigler, Doctor J. Aulin

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources